COMPANY

iBio

HQ: San Diego, CA source · ibioinc.com ↗ · Mid-Atlantic

Keywords: metabolic obesity antibody IBIO-600

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $25.99M (Form D filed Jan 22, 2026); 1 role open. SEC Form D 0001104659-26-005775 (Jan 22, 2026)
Evidence (1 event)
- Jan 22, 2026 · SEC Form D 0001104659-26-005775
  Name of Issuer: iBio, Inc.; CIK: 1420720; Address: San Diego, CA; Submission type: D; Filing date: 2026-01-22; Industry Group: Biotechnology; Date of First Sale: 2026-01-08; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 25985431; Total Amount Sold: 25985431; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

May 24, 2026 Trial start Phase 1: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults source ↗
Aug 19, 2025 Raise Follow-on offering: $50M (total, as published), announced Aug 19, 2025. Source: SEC filing. source ↗
Apr 22, 2025 Partnership Partnership / licensing announced Apr 22, 2025. Source: SEC filing. source ↗
Jan 2, 2025 Partnership Partnership / licensing: upfront $750,000 paid by the company to the licensor (in-licensing; not money received), announced Jan 2, 2025. Source: SEC filing. source ↗

2027-05 (ESTIMATED) · Phase 1 · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults · NCT07487376

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $50.0M. Last 2 years.

Aug 19, 2025 Follow-on offering: $50M (total, as published), announced Aug 19, 2025. Source: SEC filing. source ↗
Apr 22, 2025 Partnership / licensing announced Apr 22, 2025. Source: SEC filing. source ↗
Jan 2, 2025 Partnership / licensing: upfront $750,000 paid by the company to the licensor (in-licensing; not money received), announced Jan 2, 2025. Source: SEC filing. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07487376	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults	Phase 1	Recruiting	May 24, 2026	2027-05 (estimated)

Form D raises come from the company’s own SEC filing (last 2 years).

2026-01-22 Raise Private raise (SEC Form D): $26.0M sold; issuer “iBio, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-05-07 Raise Private raise (SEC Form D): $11.1M sold; issuer “iBio, Inc.”. Verified from the SEC filing. SEC filing ↗

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18